Pomalidomide is an antineoplastic medication used for the treatment of AIDS-related Kaposi sarcoma in patients who have not responded well to highly active antiretroviral therapy (HAART). It is also used to treat Kaposi sarcoma in patients who do not have HIV infection (HIV-negative). Additionally, pomalidomide is prescribed for the treatment of multiple myeloma in certain cases. Pomalidomide works by modulating the immune system and inhibiting cancer cell growth.
Parent: Pomalidomide
Parent: Pomalidomide
Parent: Pomalidomide
Parent: Pomalidomide
Parent: Pomalidomide
Parent: Pomalidomide
Parent: Pomalidomide
Impurities in pomalidomide can arise during its synthesis, handling, or storage. Ensuring the purity of the medication is crucial to maintain its efficacy and safety.
Related Substances
These are byproducts or intermediates formed during the manufacturing process of pomalidomide. Regulatory limits are imposed to ensure they remain within acceptable levels.
Degradation Products
Pomalidomide can degrade when exposed to light, heat, or moisture, which can reduce its potency. Proper storage in a cool, dry place is essential to maintain its stability.
Residual Solvents
Trace amounts of solvents used during the production process may remain in the final product. These are strictly regulated to meet safety standards.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are used to detect and quantify impurities in pomalidomide formulations.
Pomalidomide is not traditional chemotherapy but is classified as an antineoplastic agent. It works by modulating the immune system, promoting cancer cell death, and inhibiting angiogenesis (the growth of blood vessels that feed tumors).
Pomalidomide belongs to the class of immunomodulatory drugs (IMiDs). These drugs are designed to enhance the immune system’s ability to target and destroy cancer cells.
Pomalidomide binds to a protein called cereblon, leading to the degradation of specific transcription factors that promote cancer cell survival. It also stimulates the immune system and inhibits angiogenesis, which helps reduce tumor growth.
Both pomalidomide and lenalidomide belong to the IMiD class and are used to treat multiple myeloma. However, pomalidomide is generally used in cases where lenalidomide and other treatments have failed. Pomalidomide is considered more potent but may have different side effect profiles.
